Payment overview · 2025
General Payments
$872.26
53 reported records · 14 companies
Healthcare provider profile · identity verified
Ramchand Thadhani, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GALLOWAY, NJ · NPI 1619035342
Verified facts
What the public records show
CMS Open Payments records show Ramchand Thadhani, M.D. received $872.26 in general payments during 2025 across 53 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 305 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 541 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 541 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Rexulti by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Aptiom by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $222.84 | 25.6% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $213.67 | 24.5% | 20 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $103.04 | 11.8% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $85.80 | 9.8% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.84 | 4.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $34.77 | 4.0% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.87 | 3.9% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $31.07 | 3.6% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $24.77 | 2.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.51 | 2.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.00 | 1.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.33 | 1.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.11 | 1.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.64 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $872.26 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $244.74 | 22 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $176.43 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $157.67 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $103.04 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $85.80 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $36.84 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $34.77 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $33.87 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $31.64 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.51 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 305 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 541 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
305 | 39 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
24 | 11 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
541 | 63 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
541 | 63 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1015 | 262 |
| Jardiance | Empagliflozin | 541 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 491 | 121 |
| Gabapentin | Gabapentin | 465 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 455 | 114 |
| Pantoprazole Sodium | Pantoprazole Sodium | 452 | 113 |
| Eliquis | Apixaban | 450 | 70 |
| Metoprolol Tartrate | Metoprolol Tartrate | 409 | 95 |
| Furosemide | Furosemide | 400 | 80 |
| Metformin Hcl | Metformin Hcl | 359 | 89 |
| Farxiga | Dapagliflozin Propanediol | 305 | 39 |
| Divalproex Sodium | Divalproex Sodium | 288 | 41 |
| Carvedilol | Carvedilol | 265 | 71 |
| Lisinopril | Lisinopril | 265 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 263 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 259 | 59 |
| Bumetanide | Bumetanide | 245 | 49 |
| Mirtazapine | Mirtazapine | 236 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 234 | 44 |
| Potassium Chloride | Potassium Chloride | 234 | 56 |
| Trazodone Hcl | Trazodone Hcl | 230 | 46 |
| Omeprazole | Omeprazole | 226 | 78 |
| Escitalopram Oxalate | Escitalopram Oxalate | 222 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 211 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 205 | 49 |
| Montelukast Sodium | Montelukast Sodium | 198 | 46 |
| Oxycodone Hcl | Oxycodone Hcl | 189 | 24 |
| Buspirone Hcl | Buspirone Hcl | 184 | 41 |
| Tramadol Hcl | Tramadol Hcl | 172 | 24 |
| Losartan Potassium | Losartan Potassium | 166 | 57 |
| Xarelto | Rivaroxaban | 159 | 13 |
| Simvastatin | Simvastatin | 153 | 39 |
| Allopurinol | Allopurinol | 149 | 43 |
| Metformin Hcl Er | Metformin Hcl | 149 | 42 |
| Glimepiride | Glimepiride | 138 | 31 |
| Sertraline Hcl | Sertraline Hcl | 129 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 126 | 50 |
| Spironolactone | Spironolactone | 115 | 28 |
| Meloxicam | Meloxicam | 114 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 23 |
| Levetiracetam | Levetiracetam | 109 | 19 |
| Clonidine Hcl | Clonidine Hcl | 101 | 25 |
| Latanoprost | Latanoprost | 98 | 18 |
| Azithromycin | Azithromycin | 94 | 56 |
| Alprazolam | Alprazolam | 92 | 23 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 92 | 30 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 92 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 92 | 18 |
| Risperidone | Risperidone | 91 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 24 |
| Warfarin Sodium | Warfarin Sodium | 84 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 82 | 15 |
| Donepezil Hcl | Donepezil Hcl | 82 | 19 |
| Finasteride | Finasteride | 81 | 24 |
| Midodrine Hcl | Midodrine Hcl | 81 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 79 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 78 | 16 |
| Entresto | Sacubitril/Valsartan | 76 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 26 |
| Ezetimibe | Ezetimibe | 73 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 27 |
| Labetalol Hcl | Labetalol Hcl | 73 | 15 |
| Famotidine | Famotidine | 72 | 32 |
| Olanzapine | Olanzapine | 71 | 11 |
| Clonazepam | Clonazepam | 70 | 14 |
| Prednisone | Prednisone | 70 | 34 |
| Januvia | Sitagliptin Phosphate | 69 | 14 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 69 | suppressed |
| Glipizide | Glipizide | 67 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 29 |
| Mupirocin | Mupirocin | 65 | 22 |
| Ramipril | Ramipril | 65 | 11 |
| Atenolol | Atenolol | 63 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 47 |
| Baclofen | Baclofen | 61 | 21 |
| Hydrocortisone | Hydrocortisone | 61 | 29 |
| Rexulti | Brexpiprazole | 61 | suppressed |
| Myrbetriq | Mirabegron | 58 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 56 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 56 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 38 |
| Valsartan | Valsartan | 53 | suppressed |
| Sucralfate | Sucralfate | 51 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 49 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 47 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 13 |
| Celecoxib | Celecoxib | 45 | 13 |
| Levofloxacin | Levofloxacin | 45 | 25 |
| Bupropion Xl | Bupropion Hcl | 43 | suppressed |
| Glipizide Er | Glipizide | 43 | 12 |
| Alendronate Sodium | Alendronate Sodium | 42 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 13 |
| Raloxifene Hcl | Raloxifene Hcl | 41 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | suppressed |
| Tradjenta | Linagliptin | 41 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 40 | suppressed |
| Irbesartan | Irbesartan | 40 | suppressed |
| Lovastatin | Lovastatin | 40 | 13 |
| Pregabalin | Pregabalin | 40 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 39 | suppressed |
| Nystatin | Nystatin | 39 | 25 |
| Clonidine | Clonidine | 38 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 38 | 11 |
| Linzess | Linaclotide | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 31 |
| Ibuprofen | Ibuprofen | 37 | 11 |
| Lactulose | Lactulose | 36 | 11 |
| Steglatro | Ertugliflozin Pidolate | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 23 |
| Megestrol Acetate | Megestrol Acetate | 35 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 34 | suppressed |
| Fluconazole | Fluconazole | 34 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 22 |
| Insulin Lispro | Insulin Lispro | 33 | 13 |
| Sodium Chloride | 0.9 % Sodium Chloride | 33 | 19 |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Cephalexin | Cephalexin | 31 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 23 |
| Torsemide | Torsemide | 31 | 14 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | 11 |
| Lorazepam | Lorazepam | 30 | 12 |
| Trulicity | Dulaglutide | 30 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 29 | 14 |
| Albuterol Sulfate | Albuterol Sulfate | 28 | 12 |
| Alogliptin | Alogliptin Benzoate | 28 | suppressed |
| Dexamethasone | Dexamethasone | 28 | 22 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 28 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | 11 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 26 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Amantadine | Amantadine Hcl | 25 | suppressed |
| Atovaquone | Atovaquone | 25 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 25 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 25 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 24 | suppressed |
| Etodolac Er | Etodolac | 24 | 13 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 24 | 13 |
| Lokelma | Sodium Zirconium Cyclosilicate | 24 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Procrit | Epoetin Alfa | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | 11 |
| Aptiom | Eslicarbazepine Acetate | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 22 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 12 |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Novolog | Insulin Aspart | 21 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 12 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Budesonide | Budesonide | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Nyamyc | Nystatin | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | 11 |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 15 | 13 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Formoterol Fumarate | Formoterol Fumarate | 15 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 15 | 14 |
| Glucagon Emergency Kit | Glucagon | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Zonisamide | Zonisamide | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Nystop | Nystatin | 13 | 12 |
| Topiramate | Topiramate | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Efavirenz | Efavirenz | 12 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 12 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $872.26 · 53 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CAPLYTA, Cologuard Collection Kit, FANAPT, FARXIGA, GEMTESA, JARDIANCE, Kerendia, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, VRAYLAR, WATCHMAN Access System | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error